Pooled safety analysis from the VOLTAIRE clinical trials of adalimumab-adbm and adalimumab reference product in patients with rheumatoid arthritis, Crohn’s disease, and chronic plaque psoriasis
In patients with RA, CD, and PsO, there were no differences between biosimilar adalimumab-adbm or the adalimumab RP regarding the rate of AEs, SAEs, discontinuations due to AEs, deaths, or any AEs of special interest.
Authors
- Richard Vinisko (ORCID: https://orcid.org/0000-0001-9045-3027)
- Dominick J. H. McCabe (ORCID: https://orcid.org/0000-0003-0493-4516)
- Stanley Cohen (ORCID: https://orcid.org/0000-0002-9226-979X)
- Shaun Bender (ORCID: https://orcid.org/0000-0002-7589-4534)
- Amy Shaberman (ORCID: https://orcid.org/0009-0001-3544-4766)
Institutions
- Metroplex Clinical Research Center (US)
- Boehringer Ingelheim (United States) (US)
Publication Details
- Journal
- Expert Opinion on Biological Therapy
- Published
- 2024-11-06
- DOI
- https://doi.org/10.1080/14712598.2024.2426637
- Primary Topic
- Microscopic Colitis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Boehringer Ingelheim